Peel Hunt reiterated their add rating on shares of Huntsworth (LON:HNT) in a research note issued to investors on Wednesday.

A number of other brokerages also recently commented on HNT. Berenberg Bank decreased their target price on Huntsworth from GBX 150 ($1.96) to GBX 140 ($1.83) and set a buy rating for the company in a research note on Tuesday, November 27th. Numis Securities restated a buy rating on shares of Huntsworth in a research note on Friday, September 28th.

Shares of HNT stock opened at GBX 105 ($1.37) on Wednesday. Huntsworth has a 52 week low of GBX 40 ($0.52) and a 52 week high of GBX 95 ($1.24).

In other Huntsworth news, insider Paul Taaffe sold 1,243,445 shares of Huntsworth stock in a transaction that occurred on Tuesday, October 9th. The stock was sold at an average price of GBX 110 ($1.44), for a total value of £1,367,789.50 ($1,787,259.24). Also, insider Neil Jones acquired 2,420 shares of Huntsworth stock in a transaction dated Monday, November 12th. The shares were acquired at an average price of GBX 112 ($1.46) per share, with a total value of £2,710.40 ($3,541.62).

About Huntsworth

Huntsworth plc operates as a healthcare communications and public relations company in the United States, United Kingdom, rest of Europe, Asia, and the Middle East and Africa. It operates through four divisions: Huntsworth Health, Red Consultancy, Grayling, and Citigate Dewe Rogerson (CDR). The Huntsworth Health division offers an integrated suite of communications services for the science, health, and wellbeing industries.

Further Reading: Diversification For Individual Investors

Receive News & Ratings for Huntsworth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Huntsworth and related companies with MarketBeat.com's FREE daily email newsletter.